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ABSTRACT
Objectives: To review the evidence for accuracy of
imaging for diagnosis of polymyalgia rheumatica
(PMR).
Methods: Searches included MEDLINE, EMBASE and
PubMed. Evaluations of diagnostic accuracy of imaging
tests for PMR were eligible, excluding reports with <10
PMR cases. Two authors independently extracted study
data and three authors assessed methodological
quality using modified QUADAS-2 criteria.
Results: 26 studies of 2370 patients were evaluated:
10 ultrasound scanning studies; 6 MRI studies; 1 USS
and MRI study; 7 18-fluorodeoxyglucose-positron
emission tomography (PET) studies; 1 plain
radiography and 1 technetium scintigraphy study.
In four ultrasound studies, subacromial-subdeltoid
bursitis had sensitivity 80% (95% CI 55% to 93%)
and specificity 68% (95% CI 60% to 75%), whereas
bilateral subacromial-subdeltoid bursitis had sensitivity
66% (95% CI 43% to 87%) and specificity 89% (95%
CI 66% to 97%). Sensitivity for ultrasound detection
of trochanteric bursitis ranged from 21% to 100%.
In four ultrasound studies reporting both subacromial-
subdeltoid bursitis and glenohumeral synovitis,
detection of subacromial-subdeltoid bursitis was more
accurate than that of glenohumeral synovitis
(p=0.004). MRI and PET/CT revealed additional areas
of inflammation in the spine and pelvis, including
focal areas between the vertebrae and anterior to the
hip joint, but the number of controls with inflammatory
disease was inadequate for precise specificity
estimates.
Conclusions: Subacromial-subdeltoid bursitis appears
to be the most helpful ultrasound feature for PMR
diagnosis, but interpretation is limited by study
heterogeneity and methodological issues, including
variability in blinding and potential bias due to case–
control study designs. Recent MRI and PET/CT case–
control studies, with blinded readers, yielded
promising data requiring validation within a diagnostic
cohort study.
Polymyalgia rheumatica (PMR) is an age-
associated, inﬂammatory musculoskeletal
disease with a lifetime risk of 2.4% for women
and 1.7% for men,1 and affects 0.7% of the
population over the age of 50 years.2 Patients
report pain and stiffness of the shoulder and/
or hip girdles, usually with elevation of
inﬂammatory markers such as C reactive
protein and erythrocyte sedimentation rate.3
Accurate diagnosis of PMR is essential, given
the impact of PMR on quality of life unless it
is treated with systemic glucocorticoids,
usually for a year or more.4 Long-term gluco-
corticoids produce a signiﬁcant risk of
adverse events.5–8 However, PMR can be mim-
icked by many other conditions,9 many of
which also respond initially to glucocorti-
coids. None of the various sets of classiﬁcation
Key messages
What is already known about this subject?
▸ Provisional American College of Rheumatology/
the European League Against Rheumatism
(ACR/EULAR) classification criteria for polymyal-
gia rheumatica (PMR) incorporate several
optional ultrasound features, with intra-articular
and extra-articular features of inflammation
weighted equally.
What does this study add?
▸ Subacromial-subdeltoid bursitis is significantly
more discriminatory for PMR compared to gle-
nohumeral synovitis, in four studies with ultra-
sound data on both features.
▸ Data mostly come from diagnostic case-control
study designs, which can overestimate values
for sensitivity and specificity.
How might this impact on clinical practice?
▸ When evaluating patients with suspected PMR,
clinicians may consider extra-articular locations
of inflammation such as bursitis as supportive,
but must bear in mind that there may be biases
in current estimates of sensitivity and specificity
of these findings.
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criteria for PMR has yet been fully validated for clinical
diagnostic use. There remains a need for additional tests
providing diagnostic information, especially where the
diagnosis is not clear-cut.
In PMR, there is inﬂammation in and around the
shoulders and hips;3 this can often be visualised using
imaging.10 Based on small, single-centre studies, it has
been hypothesised that PMR compared to RA has pre-
dominantly extra-articular rather than intra-articular
imaging abnormalities.11–14 However, the latest, data-
driven provisional international classiﬁcation criteria for
PMR give equal weighting to extra-articular and
intra-articular ultrasound features.15 Since extra-articular
features such as subacromial-subdeltoid bursitis (SAB)
and trochanteric bursitis are commonly seen with normal
ageing,16 17 it is important to compare any imaging ﬁnd-
ings with those from non-PMR controls of similar ages.
The objective of this study was to review the evidence
regarding the accuracy of musculoskeletal imaging for
the diagnosis of PMR.
METHODS
Data sources and searches
The systematic review protocol was uploaded to the
PROSPERO database before running searches (registra-
tion number CRD42013005734). The reference standard
was deﬁned as a rheumatologist’s diagnosis of PMR,
without any better explanation of the presenting symp-
toms found during follow-up. Potential sources of het-
erogeneity, including study setting, eligibility criteria,
technical aspects of the imaging and glucocorticoid
therapy were pre-deﬁned. A PICO-structured search was
conducted to identify relevant studies in Pubmed, Ovid
MEDLINE (1966−) and EMBASE (including EMBASE
Classic) (table 1).
Study selection
A study was eligible if it included humans with either
suspected PMR (diagnostic cohort design), or both a
PMR group and a comparator non-PMR group (diagnos-
tic case–control design), with systematic application of
imaging test(s). Expert (rheumatologist) diagnosis was
the minimum acceptable reference standard. Diagnostic
accuracy data had to be extractable in 2×2 format (true
positives, true negatives, false positives, false negatives).
Non-systematic review articles, case reports and case
series of less than 10 patients were excluded. No lan-
guage restrictions were made. Case reports were
excluded by the reviewers manually, rather than by using
ﬁlters. Meeting abstracts (previous 2 years of British
Society for Rheumatology (BSR), European League
against Rheumatism (EULAR) and American College of
Rheumatology (ACR) conferences) were also screened,
and experts in the ﬁeld were contacted, to identify
studies potentially in press or not fully published.
Citations were exported to EndNote, duplicates removed
in EndNote and results exported to Microsoft Excel.
Table 1 Search strategy
Pubmed:
Polymyalg* AND (imaging OR ultrasono*
OR sonograph* OR echogr* OR “computed
tomography” OR “computer assisted
tomography” OR “bone scan” OR “nuclear
medicine” OR “scintigraph*” OR “PET” OR
“positron” OR “MRI” OR “magnetic”)
Ovid Medline:
1 Polymyalgia Rheumatica/
2 polymyalgi$.mp
3 PMR.tw
4 exp Rheumatic Diseases/
5 3 and 4
6 1 or 2 or 5
7 human/
8 (editorial or comment or historical article or
review).pt
9 7 not 8
10 exp “diagnostic imaging”/
11 (diagnostic imaging).mp
12 ri.fs
13 ra.fs
14 us.fs
15 mri.mp
16 (magnetic resonance).mp
17 (mr imaging).mp
18 mr scan$
19 mr.ti
20 exp ultrasonography/
21 ultrasound.mp
22 ultrason$.mp
23 echograph$.mp
24 sonograph$.mp
25 doppler$.mp
26 us.ti
27 scintigraph$.mp
28 positron.mp
29 PET.ti
30 ct.ti
31 radiograph$.mp
32 x-ray$.mp
33 or/10–32
34 6 and 9 and 33
Ovid EMBASE:
1 exp rheumatic polymyalgia/
2 polymyalgi$.mp
3 PMR.tw
4 exp rheumatic disease/
5 3 and 4
6 1 or 2 or 5
7 limit 6 to human
8 limit 6 to editorial
9 limit 6 to review
10 7 not (8 or 9)
11 diagnostic imaging.mp.
12 exp diagnostic imaging/
13 radiodiagnosis/
14 exp echography/
15 exp computer assisted tomography/
16 exp nuclear magnetic resonance imaging/
Continued
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Data extraction and quality assessment
A study quality assessment tool, based on QUADAS-2,18
and encompassing internal validity (risk of bias: test reli-
ability, blinding to index test/clinical information,
incorporation bias, diagnostic review bias) and external
validity (relevance to our review question: participant
selection, spectrum of disease and comparator condi-
tion, timing of test in relation to glucocorticoid treat-
ment) was agreed in advance. Two reviewers (SLM and
GK) independently extracted study characteristics
(design, clinical spectrum, reference standard) and diag-
nostic accuracy data for the index test(s) of each study.
Corresponding authors were contacted by email where
queries arose. Assessment of methodological limitations
and between-study clinical heterogeneity was guided by
the study quality assessment tool. Data were entered into
Review Manager V.5.2 (RevMan) and exported to Excel.
Data synthesis and analysis
For each imaging feature, where 4 or more studies were
available, meta-analysis was performed in Stata SE V.12
(StataCorp, Texas, USA) with calculation of overall sensi-
tivity, speciﬁcity and likelihood ratios (LRs) using the
bivariate model,19 and graphed using RevMan, allowing
visualisation of between-study statistical heterogeneity.
Inﬂuential studies were identiﬁed by plotting Cook’s dis-
tance for each study. Where fewer than four studies were
available, 95% CIs for sensitivity, speciﬁcity and LRs for
each study were calculated using a spreadsheet.20 If a
cell in the 2×2 table for a study contained a 0, 0.5 was
added to each cell to avoid division-by-zero.
To directly compare accuracy of speciﬁc couples of
tests, we used Hierarchial Summary Receiver-Operator
Characteristic Curve (HsROC) modelling,21 with test
type as a covariate. We did so with paired data only (data
from studies where both tests were evaluated together),
to control for study-based biases. We ﬁrst assessed
whether the sROC’s for the two tests had similar shapes
(the beta parameter), as sROC’s with different shapes
will cross and whether one test is better than the other
or not becomes threshold-dependent.22 Where the two
sROC’s had similar shapes, we were able to compare
overall accuracy using the α parameter (indicating prox-
imity to the top left hand corner of the ROC space).
Analysis was performed using PROC NLMIXED in SAS
V.9.3 (SAS Institute, North Carolina, USA).
RESULTS
Literature searches were completed on 2 October 2013,
yielding 1764 citations (ﬁgure 1). We identiﬁed 87 arti-
cles for full text review of which 23 studies from the ori-
ginal searches were chosen for full evaluation, with three
further added on updating searches ( January 2015): 10
ultrasound scanning studies (including one published in
full text on the updated search23); 6 MRI studies; 1 USS
and MRI study; 7 18-ﬂuorodeoxyglucose-positron emis-
sion tomography (PET) studies (including two published
in full text when the search was updated24 25); 1 plain
radiography26 and 1 technetium scintigraphy27 study.
These last two studies did not meet our review inclusion
criteria, one because of a lack of clear distinction
between PMR and non-PMR26 and the other because it
was published in 1976 and we could not exclude the pos-
sibility that changes in deﬁnition of the diagnostic refer-
ence standard may have occurred since then.27
Additionally, we reviewed four longitudinal studies.28–31
Vascular imaging studies in patients with a diagnosis of
PMR were also initially reviewed (six ultrasound and two
PET), but subsequently excluded as the primary purpose
of these studies was to diagnose giant cell arteritis in
patients presenting with PMR symptoms.
Study characteristics and results of quality assessment
are shown in table 2. All but one of the studies we identi-
ﬁed used a diagnostic case–control design, which is asso-
ciated with inﬂation of sensitivity and speciﬁcity
estimates because of the ‘grey cases’ seen in real-life clin-
ical practice but omitted from the study.32 Other
common sources of bias in this analysis included incom-
plete blinding of the person(s) performing the imaging
test, diagnostic review bias (incomplete blinding of the
diagnostician acting as reference standard) and spec-
trum bias (studies were generally conducted in academic
Table 1 Continued
Pubmed:
Polymyalg* AND (imaging OR ultrasono*
OR sonograph* OR echogr* OR “computed
tomography” OR “computer assisted
tomography” OR “bone scan” OR “nuclear
medicine” OR “scintigraph*” OR “PET” OR
“positron” OR “MRI” OR “magnetic”)
17 exp positron emission tomography/
18 ct.ti
19 (mr imaging).mp
20 (magnetic resonance).mp
21 mri.mp
22 mr.ti
23 pet.mp
24 positron.mp
25 scintigraph$.mp
26 sonograph$.mp
27 ultraso$.mp
28 echograph$.mp
29 doppler$.mp
30 us.ti
31 exp ultrasound
32 di.fs
33 radiograph$.mp
34 x-ray$.mp
35 or/11–34
36 10 and 35
The search was performed by combining the following search
terms: polymyalgia/polymyalgic and (ultrasound or radiograph or
X-ray or imaging or CT or MRI or PET or CT or isotope bone scan
or positron emission tomography or MR). No language restrictions
were made, in case the abstract reveals useful information.
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rheumatology centres) (table 2). Table 3 summarises the
accuracy of each imaging feature in PMR, using
meta-analysis where appropriate. Original data used to
create this table and further details regarding compara-
tor subpopulations are found in the online supplemen-
tary. Many different abnormalities were reported by the
studies, reﬂecting the widespread localisation of inﬂam-
mation in PMR.
Accuracy of bursitis imaging (extracapsular inflammation)
Meta-analysis of four USS studies gave a sensitivity of
80% (95% CI 55% to 93%) and speciﬁcity of 68% (60%
to 75%) for SAB; the same studies showed a sensitivity of
66% (36% to 87%) and speciﬁcity 89% (66% to 97%)
for bilateral SAB. Examination of the HsROC plot indi-
cates substantial heterogeneity of discrimination, with an
early study33 showing much higher diagnostic accuracy
than subsequent studies (ﬁgure 2).
Data on trochanteric bursitis were variable; very high
sensitivity of ultrasound in an early single-centre study34
was not replicated in a later multicentre study.15
Pelvic-girdle symptoms were required for inclusion in the
earlier study, whereas the later study required shoulder
symptoms but did not require pelvic-girdle symptoms.
Other bursal sites around the hip/pelvic region
(ischiogluteal, iliopsoas), while reportedly more speciﬁc
for PMR than trochanteric bursitis, are technically difﬁ-
cult to detect using ultrasound compared to MRI.34
Although a PET/CT study suggested inﬂammation
around the ischial tuberosity may be informative for
PMR diagnosis, the sample size was small, and thus CIs
for sensitivity and speciﬁcity are wide;35 sensitivity on an
earlier MRI study was only 25%.34 Similarly, inﬂamma-
tion (bursitis) between posterior vertebral elements,
detectable by PET/CT25 35 or MRI,36 37 appeared to be
highly speciﬁc compared to age-matched controls
without inﬂammatory rheumatic disease, but may also
be observed in RA;25 most of the RA comparator
patients were taking prednisolone (D Camellino, per-
sonal communication, January 2015). PET/CT can also
identify iliopsoas (iliopectineal) bursitis, sometimes seen
in RA as well.24
Accuracy of imaging intracapsular inflammation and fluid
around long head of biceps tendon
Synovitis at shoulder (glenohumeral) or hip (coxofe-
moral) joints, and ﬂuid around the long head of biceps
tendon (which is related to synovial inﬂammation, since
this space is synovium-lined and also communicates with
the glenohumeral joint itself), were reported by several
studies. Combining the ultrasound studies, glenohum-
eral synovitis had a sensitivity of 62% (95% CI 46% to
76%) and speciﬁcity of 58% (45% to 69%), and hip
synovitis had a sensitivity of 33% (24% to 43%) and spe-
ciﬁcity of 78% (66% to 87%). MRI and PET/CT were
much more sensitive for detecting hip synovitis in PMR,
but with a loss of speciﬁcity.
Comparison with RA
Comparison with RA may identify imaging features spe-
ciﬁc to PMR and not seen in other inﬂammatory joint
diseases. Two ultrasound studies recruited only patients
with RA as controls. In both studies, to minimise the risk
of misclassiﬁcation, cases and controls were selected on
the basis of already having an established diagnosis of
(treated) PMR or RA. Methodological quality was difﬁ-
cult to assess in the earlier study,38 but the later study39
recruited only relapsing patients with new-onset bilateral
shoulder pain; the authors reported in correspondence
with us that low-dose prednisolone treatment did not
seem to affect the ultrasound ﬁndings. It is difﬁcult to
recruit large numbers of patients with untreated RA and
elevated inﬂammatory markers. One PET/CT study
recruited 10 untreated RA patients24 but in another, the
RA patients were on treatment.40
Combined features (defined by the provisional ACR/EULAR
classification criteria for PMR
In the provisional ACR/EULAR classiﬁcation criteria for
PMR,15 ultrasound features of inﬂammation were
Figure 1 Flow chart for systematic review.
4 Mackie SL, et al. RMD Open 2015;1:e000100. doi:10.1136/rmdopen-2015-000100
RMD Open
Table 2 Assessment of methodological quality in diagnostic studies: summary of major biases identified
Study
Index test:
imaging
modality
Who performed index test,
were they blinded to clinical
data, was inter/intra-rater
reliability reported?
Prospective
study?
Does PMR spectrum
appear realistic
according to
information
given? Did any
also have GCAs?
Consecutive
selection of
participants?
Comparator
condition(s):
realistic?
Reference
standard; who
performed it,
when?
Did all
participants
receive all
tests?
Free from
incorporation
bias?
Free from
diagnostic
review bias?
Did
participants
have index
test
before
receiving
glucocorticoid
treatment?
Musculoskeletal ultrasound (MSK USS)
Dasgupta
et al15*†
MSK USS
shoulders,
hips
Rheumatologist or radiologist,
one per site; reliability
reported separately (Scheel
et al, 2009); at some sites
sonographer was clinical
assessor
Yes Yes; none had GCA No Yes: >50 years,
<12 weeks’
history of
bilateral
shoulder pain,
not felt to be
PMR
Clinical
diagnosis; by
investigator;
after 6 months
5 PMR and
15 controls
did not have
scans
Yes—
diagnosis
made before
USS, and
assessors told
not to use
USS findings
in making
diagnosis
Sonographer
and clinical
assessor
were
sometimes
same person
Yes
Ruta
et al39*†
MSK USS
shoulders
Single
rheumatologist-sonographer
blinded to clinical data;
reliability not reported
Yes Maybe: relapsing PMR
(new-onset bilateral painful
shoulder and prior
diagnosis PMR); none had
GCA
Yes Maybe:
relapsing RA
(new-onset
bilateral painful
shoulder and
prior diagnosis
of RA)
PMR: clinical
diagnosis
+Healey criteria;
RA: ACR 2010
criteria; by
treating
rheumatologist
Yes Yes Yes No; were on
≤10 mg
prednisolone;
most were on
2–4 mg;
treatment did
not seem to
affect USS
findings
Falsetti
et al44†
MSK USS at
multiple
sites
Single
rheumatologist-sonographer,
not blinded to clinical data;
reliability not reported
Yes Yes: all participants referred from primary care with
polymyalgic syndrome fulfilling Bird criteria; one developed
GCA later. All participants drawn from this same population
(single-gate study design). 29/61 (47.5%) had final diagnosis
PMR. Many of those with RA were seropositive
Clinical
diagnosis; by 2
rheumatologists,
after 1 year
Yes No No Yes
Cantini
et al34
MSK USS
hips and
MRI pelvic
girdle
Two radiologists for each test
(unclear whether these were
same people), unclear
whether blinded to clinical
data (note alternating
recruitment of cases/2
controls); reliability not
reported
Yes A subset: PMR with pelvic
girdle involvement; 3 also
had biopsy-proven GCA;
none developed RA (1987
ACR criteria) after average
follow-up 26 months
Yes Maybe: next 2
consecutive
outpatients
>50 years with
active rheumatic
disease (RA/
PsA/OA) and
bilateral hip
ache
Clinical
diagnosis
+Healey criteria
PMR, followed
up to ensure no
evolution to RA
Only 10 of
40 controls
had MRI
(unclear how
these were
selected)
Yes Unclear Yes for PMR;
unclear for
controls
Frediani
2002†45
MSK USS at
multiple
sites
Two rheumatologist-
sonographers, blinded to
diagnosis; “medium rates
concordance [agreement]”
reported but no test statistics
quoted
Yes Yes: “PMR patients with a
relatively certain
diagnosis”—Healey
criteria; 2 also had GCA
Yes No: RA (ARA
1987 criteria);
SpA (ESSG
criteria)
Clinical
diagnosis
+Healey criteria
PMR; 2-year
follow-up to
confirm
diagnosis
Yes Yes No, but
diagnosis not
changed
after USS
Yes
Continued
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Table 2 Continued
Study
Index test:
imaging
modality
Who performed index test,
were they blinded to clinical
data, was inter/intra-rater
reliability reported?
Prospective
study?
Does PMR spectrum
appear realistic
according to
information
given? Did any
also have GCAs?
Consecutive
selection of
participants?
Comparator
condition(s):
realistic?
Reference
standard; who
performed it,
when?
Did all
participants
receive all
tests?
Free from
incorporation
bias?
Free from
diagnostic
review bias?
Did
participants
have index
test
before
receiving
glucocorticoid
treatment?
Cantini
et al33
MSK USS
shoulders
Two radiologists together,
blinded to clinical diagnosis
(but note recruitment of 2
controls after each case);
reliability not reported
Yes Yes: >1 month pain neck
and shoulder girdle;
morning stiffness> 1 h;
ESR>40; 5 also had
biopsy proven GCA;
follow-up for mean
8 months to exclude those
fulfilling 1987 ARA RA
criteria
Yes Maybe: next 2
consecutive
outpatients
>50 years with
bilateral
shoulder aching,
stiffness (RA/
PsA/SpA/OA/
FM/CTD)
Clinical
diagnosis
+Healey criteria;
by 1 of 4
rheumatologists;
follow-up to
confirm
diagnosis
Yes Yes Unclear; but
participant
selection
protocol
implies
participants
did not
switch
between
case/control
groups
Yes for PMR,
unclear for
controls
Coari et al38 MSK USS
shoulders
Two
rheumatologist-sonographers,
unclear whether blinded to
clinical data; reliability not
reported
Not stated
but implied
No: treated PMR; not
stated whether any had
GCA
Not stated No: treated;
one-third of RA
patients erosive
Clinical
diagnosis (ARA
1987 for RA);
not stated by
whom or
whether followed
up
Only PMR
each had
both
shoulders
scanned;
unit of
analysis was
shoulder not
patient
Yes Unclear No
Lange
et al46
MSK USS
shoulders
Not stated; reliability not
reported
Not stated
but implied
Yes: >60 years, pain and
several hours’ morning
stiffness of shoulders,
neck and/or pelvic girdle,
limited motion in neck and
shoulder, ESR>45,
response to prednisolone
30 mg or less); 6 had
headache, 2 had
biopsy-proven GCA
Not stated Maybe: “initially
had similar
complaints (to
the PMR cases)
… involvement
of arthritis in
additional joints
and bony
erosions”
Clinical
diagnosis; not
stated by whom
or whether
followed up
Yes Yes (implied
but not stated)
Unclear Yes (implied
but not stated)
Lange
et al47
MSK USS
shoulders
Not stated; reliability not
reported
Not stated
but implied
Yes: >60 years, pain and
several hours’ morning
stiffness of shoulders,
neck and/or pelvic girdle,
>4 weeks duration
symptoms, ESR>45,
response to prednisolone
30 mg or less); 5 had
headache, 4 had
biopsy-proven GCA
Not stated Maybe: “initially
had similar
complaints (to
the PMR cases)
… involvement
of arthritis in
additional joints
and bony
erosions”
Clinical
diagnosis; not
stated by whom
or whether
followed up
Yes Yes (implied
but not stated)
Unclear Yes (implied
but not stated)
Macchioni
et al23
MSK USS
shoulders,
hips
Single
rheumatologist-sonographer;
blinding to clinical data not
stated; reliability not reported
No Yes: patients seen with
suspected PMR; patients
with GCA excluded
Yes No: patients in
early arthritis
clinic; no
requirement for
comparable
symptoms
Clinical
diagnosis;
confirmed at
1 year by 2 lead
authors
Yes Unclear No Yes
Continued
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Table 2 Continued
Study
Index test:
imaging
modality
Who performed index test,
were they blinded to clinical
data, was inter/intra-rater
reliability reported?
Prospective
study?
Does PMR spectrum
appear realistic
according to
information
given? Did any
also have GCAs?
Consecutive
selection of
participants?
Comparator
condition(s):
realistic?
Reference
standard; who
performed it,
when?
Did all
participants
receive all
tests?
Free from
incorporation
bias?
Free from
diagnostic
review bias?
Did
participants
have index
test
before
receiving
glucocorticoid
treatment?
MRI
Salvarani
et al37
1.5 T MRI
lumbar spine
(bursitis)
Radiologist; blinded to clinical
findings and diagnosis;
reliability not reported
Yes A subset: PMR by Chuang
criteria+pelvic girdle
symptoms; none had GCA
Yes Maybe: treated
patients with
lumbar pain
(SpA/OA/RA)
Clinical
diagnosis
+Chuang
criteria, followed
up for 10–16
months to
exclude RA
(ARA 1987) or
other conditions
Yes Yes Yes Yes for PMR,
unclear for
controls
Cimmino
et al40
0.2 T MRI
hands
(extremity
MRI)—
tenosynovitis
Two rheumatologists and one
PhD, blinded to diagnosis;
reliability not reported but
Parodi et al 2006 quoted in
support
Yes Yes: PMR by Chuang
criteria; none had GCA
Yes for PMR,
not for
controls
No: Healthy
controls of
similar ages, no
mention of
symptoms
Clinical
diagnosis
+Chuang
criteria, followed
for 8–124
months to
exclude GCA,
RA and other
erosive disease
Yes but 4
hands could
not be
interpreted
Yes Yes Yes
Salvarani
et al36
1 T MRI
cervical
spine
(bursitis)
One radiologist, blinded to
clinical data and diagnosis
(but note alternating
recruitment of cases,
controls); reliability not
reported
Yes Yes: PMR (reference
Salvarani review 2002);
none had GCA
Yes No: Next
patients with
neck pain seen
after PMR
patients
Clinical
diagnosis
+criteria;
followed for
10–16 months to
exclude other
conditions
Yes Yes Yes Yes
Marzo
et al13
1.5 T MRI of
most
swollen
hand
One assessor per MRI
feature, blinded to clinical
data; reliability not reported
Yes No: Bird criteria+MCP joint
swelling
Yes for RA,
not stated for
PMR
No: ARA 1987
criteria+MCP
joint swelling
Clinical
diagnosis+Bird
criteria; followed
for mean of
6 years
Yes Yes Yes Yes except for
one PMR
patient
McGonagle
et al12
1.5 T MRI
shoulder
Two radiologists, blinded to
clinical data; reliability not
reported
Yes Yes: untreated PMR and
bilateral shoulder disease
without peripheral
arthropathy
No No: early RA
fulfilling 1987
ARA criteria
Clinical
diagnosis; no
follow-up
reported to
exclude other
conditions
Only 6/14
PMR
patients had
both
shoulders
imaged
Yes Yes Yes for PMR;
not for 8/14 RA
Salvarani
et al48
0.5 T MRI
shoulder
One radiologist, blinded to
clinical data and diagnosis;
reliability not reported
Yes Yes: Healey criteria PMR;
none had GCA
Unclear No:
elderly-onset RA
by modified
1987 ARA
criteria, with
clinical evidence
shoulder
involvement
Clinical
diagnosis
+Healey criteria;
no follow-up
reported to
exclude other
conditions
The first 4
PMR had
both
shoulders
imaged; after
that only one
shoulder
Yes Yes Yes
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Table 2 Continued
Study
Index test:
imaging
modality
Who performed index test,
were they blinded to clinical
data, was inter/intra-rater
reliability reported?
Prospective
study?
Does PMR spectrum
appear realistic
according to
information
given? Did any
also have GCAs?
Consecutive
selection of
participants?
Comparator
condition(s):
realistic?
Reference
standard; who
performed it,
when?
Did all
participants
receive all
tests?
Free from
incorporation
bias?
Free from
diagnostic
review bias?
Did
participants
have index
test
before
receiving
glucocorticoid
treatment?
18F-fluorodeoxyglucose—positron emission tomography (FDG-PET)
Yamashita
et al35
FDG-PET/
CT whole
body
Not stated who reported test;
unclear whether blinded to
clinical info; reliability not
reported
No No: inpatients, having
PET/CT to exclude other
diseases for example,
suspected malignancy;
none had clinical evidence
GCA
Yes No (other
rheumatic
diseases with
suspected
malignancy;
11/17 RA)
Clinical
diagnosis
+Chuang
+Healey criteria;
length of
follow-up not
specified
Yes Unclear No Yes for PMR,
not stated for
controls
Camellino
et al25†
FDG-PET/
CT
Rheumatologist and
radiologist, blinded to clinical
data (pers comm); reliability
not reported
Yes Little information on how
patients were identified
Yes No (65 matched
controls with no
inflammatory
disease; 10 with
treated RA)
Fulfilled Bird and
ACR/EULAR
criteria; median
follow-up
22 months
Yes Yes Probably Yes for PMR/
controls, no for
RA
Takahasi
et al24†
FDG-PET/
CT
Radiologists, blinded to
clinical data [pers comm];
reliability not reported
No No: inpatients and
outpatients, having PET/
CT to exclude other
diseases, for example,
suspected malignancy;
none had clinical evidence
of GCA
Yes Maybe
(untreated,
elderly-onset
RA)
Diagnosed by
attending
doctors prior to
PET/CT (pers
comm);
diagnosis did not
change on
follow-up (pers
comm). and
verified by
classification
criteria
Yes Yes Yes Yes
The PET or PET/CT studies that did not report data extractable into 2×2 table format are not listed here. Before-after or prognostic studies, if they did not report data extractable into 2×2 table format, are not reported here.
Incorporation bias means where the imaging (index test) informs the diagnosis (reference standard).
Diagnostic review bias means where the diagnosis (reference standard) was carried out or verified with knowledge of the imaging (index test).
*Further data were supplied by corresponding authors on request.
†Methodological details supplied by corresponding authors on request.
ACR, American College of Rheumatology; ARA, American Rheumatism Association; CTD, connective tissue disease; ESR, erythrocyte sedimentation rate; EULAR, the European League Against Rheumatism; FM, fibromyalgia; GCA, giant
cell arteritis; MCP, metacarpophalangeal; OA, osteoarthritis; PET/CT, positron emission tomography CT; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SpA, spondyloarthropathies.
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Table 3 Summary data for individual tests
Anatomical finding Studies (imaging modality)
Sensitivity
(95% CI), %
Specificity
(95% CI), %
Positive likelihood
ratio (95% CI)
Negative likelihood
ratio (95% CI)
Cervical interspinous bursitis Salvarani et al36 (MRI) 0.83 (0.55 to 0.95) 0.69 (0.42 to 0.87) 2.7 (1.2 to 6.4) 0.24 (0.065 to 0.90)
Cervical interspinous bursitis, comparator no
inflammation
Camellino et al25 (PET/CT) 0.10 (0.05 to 0.19) 0.99 (0.93 to 1.00) 13 (0.8 to 226) 0.9 (0.91 to 0.99)
Lumbar interspinous bursitis Salvarani et al37 (MRI) 0.60 (0.31 to 0.83) 0.91 (0.62 to 0.98) 6.6 (1.0 to 46) 0.4 (0.20 to 0.96)
Lumbar interspinous bursitis, comparator no
inflammation
Camellino et al25 (PET/CT) 0.46 (0.35 to 0.48) 0.99 (0.93 to 1.00) 61 (3.8 to 977) 0.54 (0.43 to 0.68)
Any interspinous bursitis Yamashita et al35 (PET/CT) 0.79 (0.52 to 0.92) 0.82 (0.59 to 0.94) 4.5 (1.5 to 13) 0.26 (0.093 to 0.73)
Subacromial bursitis on at least one side Cantini et al33 (USS) 0.96 (0.88 to 0.99) 0.78 (0.70 to 0.85) 4.4 (3.1 to 6.2) 0.04 (0.01 to 0.18)
Frediani et al45 (USS) 0.70 (0.56 to 0.81) 0.61 (0.51 to 0.70) 1.8 (1.3 to 2.4) 0.49 (0.31 to 0.77)
Falsetti et al44 (USS) 0.79 (0.62 to 0.90) 0.59 (0.42 to 0.74) 2.0 (1.2 to 3.1) 0.35 (0.16 to 0.75)
Dasgupta et al15 (USS) 0.56 (0.47 to 0.65) 0.65 (0.58 to 0.72) 1.6 (1.2 to 2.1) 0.67 (0.53 to 0.85)
Cantini et al33 (USS)*
Frediani et al45 (USS)
Falsetti et al44 (USS)
Dasgupta et al15 (USS)
0.80 (0.55 to 0.93) 0.68 (0.60 to 0.75) 2.5 (1.6 to 3.8) 0.30 (0.11 to 0.81)
Subacromial bursitis on at least one side:
comparator RA
Salvarani et al48 (MRI) 0.96 (0.73 to 1.00) 0.75 (0.44 to 0.92) 3.86 (1.3 to 11) 0.05 (0.003 to 0.74)
Coari et al38 (USS) 0.09 (0.03 to 0.24) 0.90 (0.84 to 0.94) 0.95 (0.29 to 3.2) 1.01 (0.89 to 1.1)
Dasgupta et al15 (USS) 0.56 (0.47 to 0.65) 0.72 (0.57 to 0.83) 2.0 (1.2 to 3.2) 0.61 (0.46 to 0.80)
Ruta et al39 (USS) 0.73 (0.56 to 0.86) 0.67 (0.49 to 0.81) 2.2 (1.3 to 3.8) 0.40 (0.21 to 0.76)
Subacromial bursitis on at least one side:
comparator painful shoulder conditions
Dasgupta et al15 (USS) 0.56 (0.47 to 0.65) 0.70 (0.55 to 0.81) 1.9 (1.2 to 2.9) 0.63 (0.48 to 0.83)
Ruta et al39 (USS) 0.55 (0.43 to 0.67) 0.75 (0.63 to 0.84) 2.2 (1.3 to 3.6) 0.60 (0.44 to 0.82)
Subacromial bursitis on both sides Cantini et al33 (USS) 0.93 (0.83 to 0.97) 0.99 (0.95 to 1.00) 106 (15 to 747) 0.07 (0.028 to 0.18)
Frediani et al45 (USS) 0.54 (0.40 to 0.67) 0.68 (0.58 to 0.76) 1.7 (1.1 to 2.5) 0.68 (0.49 to 0.94)
Falsetti et al44 (USS) 0.69 (0.51 to 0.83) 0.78 (0.61 to 0.89) 3.2 (1.6 to 6.3) 0.40 (0.22 to 0.70)
Dasgupta et al15 (USS) 0.32 (0.24 to 0.41) 0.88 (0.81 to 0.92) 2.6 (1.6 to 4.2) 0.78 (0.68 to 0.89)
Cantini et al33 (USS)*
Frediani et al45 (USS)
Falsetti et al44 (USS)
Dasgupta et al15 (USS)
0.66 (0.36 to 0.87) 0.89 (0.66 to 0.97) 6.2 (1.2 to 32) 0.38 (0.15 to 0.97)
Subacromial bursitis on both sides: comparator
RA
Dasgupta et al15 (USS) 0.32 (0.24 to 0.41) 0.78 (0.64 to 0.88) 1.5 (0.8 to 2.7) 0.87 (0.64 to 0.88)
Ruta et al39 (USS) 0.37 (0.22 to 0.55) 0.97 (0.83 to 0.99) 11 (1.5 to 80) 0.66 (0.83 to 0.99)
Iliopsoas bursitis Cantini et al34 (MRI) 0.50 (0.30 to 0.70) 0.80 (0.50 to 0.94) 2.5 (0.67 to 9.3) 0.63 (0.37 to 1.1)
Cantini et al34 (USS) 0.30 (0.15 to 0.50) 0.90 (0.77 to 0.96) 3.0 (0.95 to 9.4) 0.78 (0.57 to 1.1)
Iliopectineal (iliopsoas) bursitis, comparator RA Takahashi et al24 0.59 (0.41 to 0.75) 0.90 (0.60 to 0.98) 5.9 (0.90 to 39) 0.45 (0.28 to 0.75)
Ischiogluteal bursitis Cantini et al34 (MRI) 0.25 (0.11 to 0.47) 0.90 (0.60 to 0.98) 2.5 (0.34 to 19) 0.83 (0.60 to 1.2)
Yamashita et al35 (PET/CT) 0.86 (0.60 to 0.96) 0.76 (0.53 to 0.90) 3.6 (1.5 to 8.8) 0.19 (0.05 to 0.69)
Cantini et al34 (USS) 0.20 (0.081 to 0.42) 0.95 (0.84 to 0.99) 4.0 (0.80 to 20) 0.84 (0.70 to 1.1)
Trochanteric bursitis on at least one side Cantini et al34 (USS) 0.98 (0.81 to 1.00) 0.70 (0.54 to 0.81) 3.2 (2.0 to 5.1) 0.03 (0.002 to 0.53)
Cantini et al34 (MRI) 0.98 (0.81 to 1.00) 0.78 (0.48 to 0.93) 4.3 (1.4 to 13) 0.031 (0.002 to 0.49)
Dasgupta et al15 (USS) 0.21 (0.15 to 0.30) 0.91 (0.84 to 0.95) 2.3 (1.2 to 4.5) 0.87 (0.78 to 0.97)
Yamashita et al35 (PET/CT) 0.71 (0.45 to 0.88) 0.88 (0.66 to 0.97) 6.1 (1.6 to 23) 0.32 (0.14 to 0.76)
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Table 3 Continued
Anatomical finding Studies (imaging modality)
Sensitivity
(95% CI), %
Specificity
(95% CI), %
Positive likelihood
ratio (95% CI)
Negative likelihood
ratio (95% CI)
Hand extracapsular: comparator RA Marzo-Ortega et al13 (MRI) 0.80 (0.49 to 0.94) 0.80 (0.49 to 0.94) 4.0 (1.1 to 14) 0.25 (0.07 to 0.90)
Shoulder extracapsular: comparator RA McGonagle et al12 (MRI) 0.64 (0.39 to 0.84) 0.86 (0.60 to 0.96) 4.5 (1.2 to 17) 0.42 (0.2 to 0.87)
Long head biceps tenosynovitis on at least one
side
Cantini et al33 (USS) 0.81 (0.70 to 0.89) 0.47 (0.38 to 0.57) 1.5 (1.2 to 1.9) 0.41 (0.23 to 0.72)
Dasgupta et al15 (USS) 0.66 (0.57 to 0.74) 0.54 (0.46 to 0.61) 1.4 (1.2 to 1.8) 0.63 (0.47 to 0.85)
Frediani et al45 (USS) 0.68 (0.54 to 0.79) 0.59 (0.49 to 0.68) 1.7 (1.2 to 2.2) 0.54 (0.35 to 0.84)
Long head biceps tenosynovitis on at least one
side: comparator RA
Coari et al38 (USS) 0.16 (0.07 to 0.32) 0.48 (0.38 to 0.58) 0.30 (0.13 to 0.69) 1.8 (1.4 to 2.3)
Dasgupta et al15 (USS) 0.66 (0.57 to 0.74) 0.44 (0.31 to 0.59) 1.2 (0.89 to 1.6) 0.76 (0.51 to 1.2)
Ruta et al39 (USS) 0.63 (0.46 to 0.78) 0.57 (0.39 to 0.73) 1.5 (0.89 to 2.4) 0.65 (0.37 to 1.1)
Lange et al46 (USS) 0.14 (0.05 to 0.33) 0.59 (0.41 to 0.74) 0.33 (0.11 to 1.0) 1.5 (1.0 to 2.1)
Coari et al38 (USS)
Dasgupta et al15 (USS)
Ruta et al39 (USS)
Lange et al46 (USS)
0.37 (0.15 to 0.66) 0.50 (0.43 to 0.57) 0.74 (0.35 to 1.6) 1.3 (0.80 to 2.0)
Salvarani et al48 (MRI) 0.47 (0.25 to 0.70) 0.67 (0.35 to 0.88) 1.4 (0.48 to 4.1) 0.80 (0.41 to 1.6)
Long head biceps tenosynovitis on at least one
side: comparator painful shoulder conditions
Coari et al38 (USS) 0.16 (0.069 to 0.32) 0.45 (0.37 to 0.54) 0.28 (0.13 to 0.65) 1.9 (1.5 to 2.4)
Dasgupta et al15 (USS) 0.66 (0.57 to 0.74) 0.60 (0.45 to 0.72) 1.6 (1.1 to 2.4) 0.57 (0.40 to 0.80)
Ruta et al39 (USS) 0.47 (0.35 to 0.59) 0.80 (0.68 to 0.88) 2.3 (1.3 to 4.1) 0.67 (0.51 to 0.87)
Long head biceps tenosynovitis on both sides Cantini et al33 (USS) 0.60 (0.47 to 0.72) 0.96 (0.90 to 0.98) 15 (5.8 to 41) 0.42 (0.30 to 0.58)
Frediani et al45 (USS) 0.38 (0.26 to 0.52) 0.68 (0.58 to 0.76) 1.2 (0.75 to 1.9) 0.91 (0.71 to 1.2)
Falsetti et al44 (USS) 0.62 (0.44 to 0.77) 0.66 (0.48 to 0.80) 1.8 (1.0 to 3.2) 0.58 (0.34 to 0.98)
Dasgupta et al15 (USS) 0.37 (0.29 to 0.46) 0.73 (0.66 to 0.80) 1.4 (0.98 to 2.0) 0.86 (0.72 to 1.0)
Cantini et al33 (USS)
Frediani et al45 (USS)
Falsetti et al44 (USS)*
Dasgupta et al15 (USS)
0.47 (0.35 to 0.58) 0.80 (0.61 to 0.91) 2.4 (0.93 to 6.0) 0.67 (0.46 to 0.95)
Long head biceps tenosynovitis on both sides:
comparator RA
Dasgupta et al15 (USS) 0.37 (0.29 to 0.46) 0.62 (0.48 to 0.75) 0.99 (0.63 to 1.5) 1.0 (0.77 to 1.3)
Ruta et al39 (USS) 0.30 (0.17 to 0.48) 0.98 (0.86 to 1.00) 19 (1.2 to 310) 0.71 (0.56 to 0.90)
Tenosynovitis of hand extensor tendons Cimmino et al40 (MRI) 0.67 (0.42 to 0.85) 0.69 (0.42 to 0.87) 2.2 (0.89 to 5.3) 0.48 (0.22 to 1.1)
Glenohumeral synovitis on at least one side Cantini et al33 (USS) 0.77 (0.65 to 0.86) 0.42 (0.33 to 0.51) 1.3 (1.1 to 1.6) 0.54 (0.32 to 0.92)
Frediani et al45 (USS) 0.66 (0.52 to 0.78) 0.65 (0.55 to 0.73) 1.9 (1.4 to 2.6) 0.52 (0.35 to 0.79)
Falsetti et al44 (USS) 0.66 (0.47 to 0.80) 0.47 (0.31 to 0.64) 1.2 (0.81 to 1.9) 0.74 (0.40 to 1.4)
Dasgupta et al15 (USS) 0.39 (0.30 to 0.48) 0.71 (0.64 to 0.78) 1.3 (0.96 to 1.9) 0.86 (0.72 to 1.0)
Cantini et al33 (USS)
Frediani et al45 (USS)
Falsetti et al44 (USS)
Dasgupta et al15 (USS)
0.62 (0.46 to 0.76) 0.58 (0.45 to 0.69) 1.5 (1.2 to 1.7) 0.66 (0.50 to 9.9)
Glenohumeral synovitis on at least one side:
comparator RA
Lange et al46 (USS) 0.41 (0.23 to 0.61) 0.34 (0.20 to 0.53) 0.62 (0.35 to 1.1) 1.7 (0.93 to 3.2)
Coari et al38 (USS) 0.66 (0.48 to 0.80) 0.52 (0.42 to 0.62) 1.4 (0.99 to 1.9) 0.66 (0.39 to 1.1)
Ruta et al39 (USS) 0.20 (0.10 to 0.37) 0.57 (0.39 to 0.73) 0.46 (0.20 o 1.1) 1.4 (0.99 to 2.0)
Dasgupta et al15 (USS) 0.39 (0.30 to 0.48) 0.63 (0.49 to 0.75) 1.1 (0.67 to 1.6) 0.97 (0.75 to 1.3)
Continued
10
M
ackie
SL,etal.RM
D
Open
2015;1:e000100.doi:10.1136/rm
dopen-2015-000100
R
M
D
O
p
e
n
Table 3 Continued
Anatomical finding Studies (imaging modality)
Sensitivity
(95% CI), %
Specificity
(95% CI), %
Positive likelihood
ratio (95% CI)
Negative likelihood
ratio (95% CI)
Lange et al46 (USS)†
Coari et al38 (USS)†
Ruta et al39 (USS)
Dasgupta et al15 (USS)
0.41 (0.26 to 0.58) 0.53 (0.45 to 0.62) 0.88 (0.58 to 1.3) 1.1 (0.82 to 1.5)
Salvarani et al48 (MRI) 0.77 (0.50 to 0.92) 0.44 (0.19 to 0.73) 1.4 (0.72 to 2.7) 0.52 (0.15 to 1.8)
Glenohumeral synovitis on at least one side:
comparator painful shoulder conditions
Coari et al38 (USS) 0.66 (0.48 to 080) 0.77 (0.69 to 0.84) 2.9 (1.9 to 4.3) 0.45 (0.27 to 0.73)
Dasgupta et al15 (USS) 0.39 (0.30 to 0.48) 0.76 (0.62 to 0.86) 1.6 (0.92 to 2.8) 0.81 (0.65 to 1.0)
Ruta et al39 (USS) 0.12 (0.058 to 0.22) 0.93 (0.84 to 0.97) 1.8 (0.54 to 5.7) 0.95 (0.84 to 1.06)
Glenohumeral synovitis on both sides Dasgupta et al15 0.26 (0.19 to 0.35) 0.83 (0.76 to 0.88) 1.5 (0.97 to 2.4) 0.89 (0.78 to 1.0)
Falsetti et al44 0.48 (0.31 to 0.66) 0.66 (0.48 to 0.80) 1.4 (0.76 to 2.6) 0.79 (0.51 to 1.2)
Frediani et al45 0.52 (0.39 to 0.65) 0.78 (0.69 to 0.85) 2.4 (1.50 to 3.7) 0.62 (0.45 to 0.84)
Glenohumeral synovitis on both sides: comparator
RA
Dasgupta et al15 0.26 (0.19 to 0.35) 0.70 (0.55 to 0.81) 0.86 (0.50 to 1.5) 1.1 (0.85 to 1.3)
Ruta et al39 0.03 (0.059 to 0.17) 0.90 (0.74 to 0.97) 0.33 (0.037 to 3.0) 1.1 (0.94 to 1.2)
Hip synovitis on at least one side Cantini et al34 (USS) 0.45 (0.25 to 0.66) 0.55 (0.40 to 0.69) 1.0 (0.55 to 1.8) 1.0 (0.62 to 1.6)
Frediani et al45 (USS) 0.40 (0.28 to 0.54) 0.81 (0.72 to 0.87) 2.1 (1.2 to 3.6) 0.74 (0.58 to 0.95)
Falsetti et al44 (USS) 0.24 (0.12 to 0.42) 0.88 (0.72 to 0.95) 1.9 (0.63 to 5.9) 0.87 (0.68 to 1.1)
Dasgupta et al15 (USS) 0.26 (0.19 to 0.36) 0.81 (0.73 to 0.87) 1.4 (0.87 to 2.3) 0.90 (0.78 to 1.0)
Cantini et al34 (USS)
Frediani et al45 (USS)
Falsetti et al44 (USS)
Dasgupta et al15 (USS)
0.33 (0.24 to 0.43) 0.78 (0.66 to 0.87) 1.5 (1.0 to 2.2) 0.86 (0.76 to 0.97)
Cantini et al34 (MRI) 0.85 (0.64 to 0.95) 0.50 (0.24 to 0.76) 1.7 (0.89 to 3.2) 0.30 (0.089 to 1.0)
Yamashita et al35 (PET/CT) 0.86 (0.60 to 0.96) 0.65 (0.41 to 0.83) 2.4 (1.2 to 4.8) 0.22 (0.058 to 0.84)
Hip synovitis on both sides Dasgupta et al15 (USS) 0.18 (0.12 to 0.26) 0.92 (0.85 to 0.95) 2.1 (1.0 to 4.3) 0.90 (0.81 to 1.0)
Frediani et al45 (USS) 0.32 (0.21 to 0.46) 0.83 (0.75 to 0.89) 1.88 (1.0 to 3.4) 0.82 (0.66 to 1.0)
Shoulder region uptake Yamashita et al35 (PET/CT) 0.86 (0.60 to 0.96) 0.29 (0.13 to 0.53) 1.2 (0.84 to 1.8) 0.49 (0.11 to 2.1)
Bilateral shoulder region inflammation Dasgupta et al15 (USS) 0.59 (0.50 to 0.68) 0.57 (0.49 to 0.65) 1.4 (1.1 to 1.7) 0.71 (0.55 to 0.92)
Macchioni et al23 (USS) 0.45 (0.39 to 0.51) 0.60 (0.47 to 0.72) 1.1 (0.79 to 1.6) 0.91 (0.71 to 1.2)
Bilateral shoulder region inflammation: comparator
painful shoulder conditions
Dasgupta et al15 (USS) 0.59 (0.50 to 0.68) 0.74 (0.61 to 0.85) 2.3 (1.4 to 3.9) 0.55 (0.42 to 0.72)
Bilateral shoulder region inflammation: comparator
RA
Dasgupta et al15 (USS) 0.59 (0.50 to 0.68) 0.35 (0.23 to 0.49) 0.91 (0.70 to 1.2) 1.2 (0.75 to 1.8)
Macchioni 2013 (USS 0.56 (0.49 to 0.63) 0.74 (0.60 to 0.85) 2.2 (1.3 to 3.7) 0.60 (0.47 to 0.76)
Hip region inflammation: comparator RA Dasgupta et al15 (USS) 0.38 (0.30 to 0.47) 0.70 (0.55 to 0.81) 1.3 (0.77 to 2.1) 0.89 (0.70 to 1.1)
Hip region inflammation: comparator painful
shoulder conditions
Dasgupta et al15 (USS) 0.38 (0.30 to 0.47) 0.83 (0.70 to 0.91) 2.3 (1.2 to 4.4) 0.74 (0.61 to 0.90)
One shoulder and one hip region inflammation Dasgupta et al15 (USS) 0.33 (0.26 to 0.42) 0.84 (0.77 to 0.89) 2.1 (1.3 to 3.2) 0.80 (0.69 to 0.92)
Macchioni et al23 (USS) 0.34 (0.27 to 0.41) 0.77 (0.68 to 0.85) 1.5 (0.97 to 2.3) 0.86 (0.74 to 1.0)
Note these are reported to 2 significant figures but note CIs are often wide. Sensitivity, specificity, positive likelihood ratio and negative likelihood ratio are given for individual tests or, where
possible, a summary value is calculated by meta-analysis. Sensitivity and specificity are given to two decimal places. Likelihood ratios are given to two significant figures unless <0.1 or >10.
*Outlier by visual inspection of HsROC.
†Influential outlier (Cooks’ distance >3). “Shoulder region inflammation”, “hip region inflammation” are defined as per ACR/EULAR provisional classification criteria for PMR.15
ACR, American College of Rheumatology; EULAR, the European League Against Rheumatism; HsROC, Hierarchial Summary Receiver-Operator Characteristic Curve; PMR, polymyalgia
rheumatica.
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combined. First, different anatomical sites from each
region were combined: shoulder region inﬂammation was
deﬁned as SAB, ﬂuid around the long head of biceps
tendon, OR glenohumeral synovitis; hip region inﬂamma-
tion was deﬁned as coxofemoral synovitis OR trochan-
teric bursitis.15 This use of OR had the effect of
increasing sensitivity of the criteria. Second, based on
the regression modelling used to deﬁne the ﬁnal classiﬁ-
cation criteria set, one point was allocated for bilateral
shoulder region inﬂammation, and one point for shoul-
der region inﬂammation plus hip region inﬂammation.
This requirement for two regions involved had the effect
of increasing speciﬁcity of the criteria. Bilateral shoulder
region involvement had a sensitivity of 59% (50% to
68%) and speciﬁcity 57% (49% to 65%), whereas having
one shoulder and one hip involved had a sensitivity 33%
(26% to 42%) and speciﬁcity 84% (77% to 89%).15 This
may reﬂect the requirement for shoulder symptoms for
inclusion of both patients and controls, whereas PMR
characteristically causes symptoms at shoulders as well as
hips. A later study produced similar sensitivity/speciﬁcity
data, with the caveat that its control population was
patients with early RA, and the completeness of sonogra-
pher and diagnostician blinding to each other’s ﬁndings
was unclear.23
Change with treatment
Comparison of before-treatment and after-treatment
ﬁndings was reported for musculoskeletal USS,28–30
MRI31 and FDG-PET.41 After 4 weeks of glucocorticoid
treatment, shoulder USS normalised in half of the
patients who had had bilateral USS abnormalities before
treatment, and this persisted to 6 months.28 In a second
study, 11/24 patients had power Doppler signal
(indicating microvascular hyperaemia, and suggesting
chronicity of inﬂammation) in at least one shoulder
structure; this was present in only 1/24 patients at
6 months. PMR still had abnormalities in shoulder ultra-
sound at 6 months compared to a group of 21 ‘normal’
patients, but this was not seen for hip ultrasound
ﬁndings.30
Prognosis
In 57 patients with PMR, the presence of power Doppler
signal prior to treatment in articular/periarticular shoul-
der structures signiﬁcantly predicted PMR relapse/recur-
rence after 6 months.29
Direct comparison of test accuracy using paired data
Only two couples of tests had sufﬁcient paired data (≥4
studies) for our analysis. The paired comparisons were
only made where the relevant tests were carried out on
cases and controls in all studies, so the same cases and
controls had both tests. Ultrasound detection of bilateral
SAB was compared to ultrasound detection of hip syno-
vitis, but the two sROC’s had different shapes and com-
parison of overall accuracy was not possible. Ultrasound
detection of subacaromial-subdeltoid bursitis was com-
pared to ultrasound detection of glenohumeral synovitis.
The two sROC’s had similar shapes, and we found ultra-
sound detection of SAB to be signiﬁcantly more accurate
than ultrasound detection of glenohumeral synovitis, for
the diagnosis of PMR (p=0.004).
DISCUSSION
Our objective was to determine whether musculoskeletal
imaging is accurate enough to be useful to support clin-
ical diagnosis of PMR. Although MRI and PET/CT
revealed potentially characteristic features of focal
inﬂammation between vertebral processes and within the
pelvis, only the USS studies had enough control patients
with inﬂammatory diseases for precise estimates of diag-
nostic accuracy. The most informative single USS feature
appeared to be bilateral SAB, with a speciﬁcity of 89%
(95% CI 66% to 97%) and sensitivity 66% (43% to
87%); however, the earliest study reported much higher
diagnostic accuracy than subsequent studies. In general,
substantial clinical and statistical between-study hetero-
geneity was noted, including important biases, and there-
fore the absolute sensitivity/speciﬁcity estimates given
here must be interpreted with great caution. The effects
of between-study heterogeneity can be minimised where
each study reported the same two tests; this pairwise
comparison across four studies showed that SAB was sig-
niﬁcantly more accurate than glenohumeral synovitis for
PMR diagnosis. This suggests that it might not be appro-
priate to weight these two features equally in diagnosing
PMR, as has been suggested by the latest criteria set.15
Several potential biases were identiﬁed during the
quality assessment. First, all studies, except one, had a
case-control study design. This would introduce
Figure 2 Summary ROC plot for bilateral subacromial
bursitis. ROC, receiver operating characteristic.
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spectrum bias and produce heterogeneity in the speciﬁ-
city estimates depending on how the controls were
recruited. The only study with a diagnostic cohort
design suffered from incorporation bias because the
ultrasound was used to help make the diagnosis.
Second, most of the reports contained little detail on
how blinding was achieved and maintained. This is par-
ticularly difﬁcult for USS, which requires close patient
contact. Recruitment of two controls following each case
could have compromised blinding and was associated
with much higher estimates of diagnostic accuracy.33 34
Blinding of the treating rheumatologist and the patient
until after the ﬁnal adjudication of reference-standard
clinical diagnosis (which may be 1 year later), would
require explicit patient consent and may not always have
been possible. There was often insufﬁcient detail on
whether and how the patients themselves were blinded
to their imaging ﬁndings, and on how frequently the
treating clinician had to be unblinded or patients
excluded from analysis because of unexpected ﬁndings
on the scan (particularly relevant for MRI and PET
studies). Lastly, intra/inter-rater reliability of imaging
test was rarely fully reported, although this was arguably
unlikely to introduce a systematic bias.
Some limitations of this analysis could have made
imaging appear less accurate than it really is. First, the
use of binary scores (present/absent) rather than
grades of intensity of inﬂammation or number of sites
involved is a limitation of diagnostic accuracy
meta-analysis methods. Second, the necessity of using
rheumatologist diagnosis as an (imperfect) reference
standard; for future studies, adding a ‘test of treat-
ment’42 might be used to improve the reference stand-
ard, since ultrasound abnormalities were associated with
complete response to glucocorticoid therapy.30 Third, it
is not known whether adding power Doppler to the
ultrasound might offer superior diagnostic accuracy for
PMR compared to grey-scale ultrasound alone.
Overall, the accuracy of musculoskeletal imaging tests
cannot currently be accurately quantiﬁed for clinical
diagnosis of PMR, primarily due to the limited amount
of published data and biases in the studies. The refer-
ence standard is still rheumatologist diagnosis, which
may use clinical intuition rather than formal criteria;43
we might expect that tests adding additional informa-
tion, including imaging tests, might help in ‘grey cases’
where the clinical diagnosis is not clear-cut, but there
are no studies recruiting these ‘grey cases’ and evaluat-
ing them without incorporation bias. Finally, if the prog-
nostic value of imaging were known, this might also have
value for clinical practice and perhaps even for patient
classiﬁcation. This type of evidence would help deter-
mine the optimal place of imaging tests in diagnostic
care pathways for patients with suspected PMR.
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